» Articles » PMID: 37664593

MYCT1 Attenuates Renal Fibrosis and Tubular Injury in Diabetic Kidney Disease

Overview
Journal iScience
Publisher Cell Press
Date 2023 Sep 4
PMID 37664593
Authors
Affiliations
Soon will be listed here.
Abstract

Tubulointerstitial abnormalities contribute to the progression of diabetic kidney disease (DKD). However, the underlying mechanism of the pathobiology of tubulointerstitial disease is largely unknown. Here, we showed that MYCT1 expression was downregulated in and DKD models. Adeno-associated virus (AAV)-Myct1 significantly attenuated renal dysfunction and tubulointerstitial fibrosis in diabetic db/db mice and downregulated Sp1 transcription and TGF-β1/SMAD3 pathway activation. In human proximal tubular epithelial cells, high glucose-induced high expression of SP1 and TGF-β1/SMAD3 pathway activation as well as overaccumulation of extracellular matrix (ECM) were abrogated by MYCT1 overexpression. Mechanistically, the binding of VDR to the MYCT1 promoter was predicted and confirmed using dual-luciferase reporter and ChIP analysis. VDR transcriptionally upregulates MYCT1. Our data reveal MYCT1 as a new and potential therapeutic target in treating DKD.

Citing Articles

Transcription factor specificity protein (SP) family in renal physiology and diseases.

Zhou W, Fang J, Jia Q, Meng H, Liu F, Mao J PeerJ. 2025; 13():e18820.

PMID: 39850832 PMC: 11756367. DOI: 10.7717/peerj.18820.


TBX21 inhibits colorectal cancer metastasis through ARHGAP29/GSK3β inhibitory signaling- and MYCT1/ZO-1 signaling-dependent manner.

Yang X, Shen X, Liu Z, Li Y, Liu H, Zhan Y Int J Biol Sci. 2025; 21(1):328-345.

PMID: 39744435 PMC: 11667819. DOI: 10.7150/ijbs.97920.


HOXD10 attenuates renal fibrosis by inhibiting NOX4-induced ferroptosis.

Li X, Ma T, Wang P, Shi H, Hai S, Qin Y Cell Death Dis. 2024; 15(6):398.

PMID: 38844470 PMC: 11156659. DOI: 10.1038/s41419-024-06780-w.


1-L Transcription of SARS-CoV-2 Spike Protein S1 Subunit.

Nahalka J Int J Mol Sci. 2024; 25(8).

PMID: 38674024 PMC: 11049929. DOI: 10.3390/ijms25084440.

References
1.
Moukayed M, Grant W . Linking the metabolic syndrome and obesity with vitamin D status: risks and opportunities for improving cardiometabolic health and well-being. Diabetes Metab Syndr Obes. 2019; 12:1437-1447. PMC: 6701609. DOI: 10.2147/DMSO.S176933. View

2.
Bermudez Y, Yang H, Saunders B, Cheng J, Nicosia S, Kruk P . VEGF- and LPA-induced telomerase in human ovarian cancer cells is Sp1-dependent. Gynecol Oncol. 2007; 106(3):526-37. DOI: 10.1016/j.ygyno.2007.05.005. View

3.
Gao P, Wei Y, Zhang Z, Zeng W, Sun D, Liu D . Synergistic effects of c-Jun and SP1 in the promotion of TGFβ1-mediated diabetic nephropathy progression. Exp Mol Pathol. 2016; 100(3):441-50. DOI: 10.1016/j.yexmp.2016.04.005. View

4.
Klaus G . Renoprotection with vitamin D: specific for diabetic nephropathy?. Kidney Int. 2008; 73(2):141-3. DOI: 10.1038/sj.ki.5002693. View

5.
Motojima M, Ando T, Yoshioka T . Sp1-like activity mediates angiotensin-II-induced plasminogen-activator inhibitor type-1 (PAI-1) gene expression in mesangial cells. Biochem J. 2000; 349(Pt 2):435-41. PMC: 1221166. DOI: 10.1042/0264-6021:3490435. View